Zev A. Wainberg, MD, MSc, discussed why neither the first-line regimen nor the second-line chemotherapy comparator altered ...
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in ...
KEYNOTE-B49 data show pembrolizumab plus chemotherapy improved PFS but not OS in PD-L1–positive HR+/HER2– advanced breast ...
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in ...
Biomarker and preclinical data support SEZ6 as a potential therapeutic target in small cell lung cancer management.
In STARBOARD, frontline encorafenib, binimetinib, and pembrolizumab improved ORR and PFS vs pembrolizumab alone in BRAF V600E ...
A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with ...
Investigators of the CEMI-LUNG study (NCT05363319) enrolled an unselected, real-world population of more than 200 patients ...
Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.
What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results